MedTrace Logo

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-06-30

Study results available
· View outcomes & findings →

Summary

This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

HLD200

DRUG

Placebo

Sponsors & Collaborators

  • Ironshore Pharmaceuticals and Development, Inc

    lead OTHER

Principal Investigators

  • Dr. Ann Childress, M.D. · Center for Psychiatry And Behavioral Medicine Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02255513 on ClinicalTrials.gov